Literature DB >> 18384725

Identification of potentially hazardous human gene products in GMO risk assessment.

Hans Bergmans1, Colin Logie, Kees Van Maanen, Harm Hermsen, Michelle Meredyth, Cécile Van Der Vlugt.   

Abstract

Genetically modified organisms (GMOs), e.g. viral vectors, could threaten the environment if by their release they spread hazardous gene products. Even in contained use, to prevent adverse consequences, viral vectors carrying genes from mammals or humans should be especially scrutinized as to whether gene products that they synthesize could be hazardous in their new context. Examples of such potentially hazardous gene products (PHGPs) are: protein toxins, products of dominant alleles that have a role in hereditary diseases, gene products and sequences involved in genome rearrangements, gene products involved in immunomodulation or with an endocrine function, gene products involved in apoptosis, activated proto-oncogenes. For contained use of a GMO that carries a construct encoding a PHGP, the precautionary principle dictates that safety measures should be applied on a "worst case" basis, until the risks of the specific case have been assessed. The potential hazard of cloned genes can be estimated before empirical data on the actual GMO become available. Preliminary data may be used to focus hazard identification and risk assessment. Both predictive and empirical data may also help to identify what further information is needed to assess the risk of the GMO. A two-step approach, whereby a PHGP is evaluated for its conceptual dangers, then checked by data bank searches, is delineated here.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18384725     DOI: 10.1051/ebr:2008001

Source DB:  PubMed          Journal:  Environ Biosafety Res        ISSN: 1635-7922


  5 in total

1.  Regeneration of mammalian cochlear and vestibular hair cells through Hes1/Hes5 modulation with siRNA.

Authors:  Xiaoping Du; Wei Li; Xinsheng Gao; Matthew B West; W Mark Saltzman; Christopher J Cheng; Charles Stewart; Jie Zheng; Weihua Cheng; Richard D Kopke
Journal:  Hear Res       Date:  2013-07-09       Impact factor: 3.208

Review 2.  Environmental risk assessment of clinical trials involving modified vaccinia virus Ankara (MVA)-based vectors.

Authors:  Martine Goossens; Katia Pauwels; Nicolas Willemarck; Didier Breyer
Journal:  Curr Gene Ther       Date:  2013-12       Impact factor: 4.391

Review 3.  Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2.

Authors:  Aline Baldo; Amaya Leunda; Nicolas Willemarck; Katia Pauwels
Journal:  Vaccines (Basel)       Date:  2021-05-03

Review 4.  General considerations on the biosafety of virus-derived vectors used in gene therapy and vaccination.

Authors:  Aline Baldo; Eric van den Akker; Hans E Bergmans; Filip Lim; Katia Pauwels
Journal:  Curr Gene Ther       Date:  2013-12       Impact factor: 4.391

Review 5.  Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination.

Authors:  Aline Baldo; Evanthia Galanis; Frédéric Tangy; Philippe Herman
Journal:  Hum Vaccin Immunother       Date:  2015-12-02       Impact factor: 3.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.